Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 20;13(24):6390. doi: 10.3390/cancers13246390

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Kaplan–Meier estimates for overall survival (OS) from liver metastasis to death according to therapy, considering the impact of surgical resection of liver metastases. (A) Surgical resection of liver metastases indicated a highly significant impact on OS of patients with MUM. (B) In order to avoid corresponding bias, comparison of survival between Cohort 1 and Cohort 2 were additionally performed only for those whose metastases were not surgically resected (n = 31), referred to as Cohort 1.1 (ICI plus liver-directed therapy exclusive surgical treatment) and Cohort 1.2 (monotherapies, combinations of systemic therapy and liver-directed therapies excluding surgical treatment).

Kaplan–Meier estimates for overall survival (OS) from liver metastasis to death according to therapy, considering the impact of surgical resection of liver metastases. (A) Surgical resection of liver metastases indicated a highly significant impact on OS of patients with MUM. (B) In order to avoid corresponding bias, comparison of survival between Cohort 1 and Cohort 2 were additionally performed only for those whose metastases were not surgically resected (n = 31), referred to as Cohort 1.1 (ICI plus liver-directed therapy exclusive surgical treatment) and Cohort 1.2 (monotherapies, combinations of systemic therapy and liver-directed therapies excluding surgical treatment).